# A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

> **NCT05984784** · PHASE1,PHASE2 · TERMINATED · sponsor: **Inmagene LLC** · enrollment: 13 (actual)

## Conditions studied

- Atopic Dermatitis
- Moderate-to-severe Atopic Dermatitis
- AD

## Interventions

- **DRUG:** Placebo
- **DRUG:** IMG-007

## Key facts

- **NCT ID:** NCT05984784
- **Lead sponsor:** Inmagene LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-09
- **Primary completion:** 2024-04-26
- **Final completion:** 2024-04-26
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Cohort 1 was completed. Cohort 2 was cancelled because data from Cohort 1 provided sufficient information for further development decision. No safety concerns were noted.
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984784, "A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05984784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*